2023年3月13日至3月16日，中(zhong)国医药董(dong)事(shi)童朝(chao)银、监(jian)事(shi)会主席强勇、监(jian)事(shi)刘志(zhi)勇、监(jian)事(shi)王亚良(liang)一行赴广东公(gong)司和湛江公(gong)司开展现(xian)场(chang)调研(yan)工作。

        调研(yan)组分别听取了广(guang)东(dong)公(gong)(gong)司(si)和湛(zhan)江公(gong)(gong)司(si)有关经(jing)营(ying)管理、主要(yao)商业(ye)模式(shi)、战略落(luo)地(di)执(zhi)行(xing)等(deng)(deng)情况(kuang)的汇报，并(bing)做了深(shen)度交(jiao)流(liu)。在调研(yan)期(qi)间，调研(yan)组分别对番禺中(zhong)心(xin)医院SPD项(xiang)目、番禺血透中(zhong)心(xin)、白云区(qu)检中(zhong)心(xin)、广(guang)东(dong)公(gong)(gong)司(si)物(wu)流(liu)中(zhong)心(xin)以及湛(zhan)江公(gong)(gong)司(si)物(wu)流(liu)中(zhong)心(xin)等(deng)(deng)进行(xing)现(xian)场考(kao)察。

       调研组充分肯定了广东公司和湛江公司近年来取得(de)的成绩，并(bing)就创新业务发展(zhan)、网络布局、管理提(ti)升和协同发展(zhan)等方(fang)面提(ti)出了相(xiang)关建议。

       中(zhong)国(guo)医药总(zong)经理(li)助理(li)、广东(dong)公(gong)(gong)司总(zong)经理(li)张惠波出席(xi)调研会(hui)议，中(zhong)国(guo)医药商(shang)业事(shi)业部相关人员列(lie)席(xi)调研会(hui)议。广东(dong)公(gong)(gong)司、湛江公(gong)(gong)司及中(zhong)国(guo)医药董事(shi)会(hui)办公(gong)(gong)室相关人员陪同。